Primary pulmonary adenocarcinoma in a 16-year-old boy
a five-year follow-up
Måreng, Ane Stillits; Langer, Seppo W; Bodtger, Uffe

Published in:
European Clinical Respiratory Journal

DOI:
10.3402/ecrj.v3.32633

Publication date:
2016

Document version:
Final published version

Document license:
CC BY

Citation for published version (APA):
Måreng, A. S., Langer, S. W., & Bodtger, U. (2016). Primary pulmonary adenocarcinoma in a 16-year-old boy: a five-year follow-up. European Clinical Respiratory Journal, 3(1), [32633]. https://doi.org/10.3402/ecrj.v3.32633

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use
This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 26. Oct. 2023
Primary pulmonary adenocarcinoma in a 16-year-old boy – a five-year follow-up

Ane Stillits Måreng, Seppo W. Langer & Uffe Bodtger

To cite this article: Ane Stillits Måreng, Seppo W. Langer & Uffe Bodtger (2016) Primary pulmonary adenocarcinoma in a 16-year-old boy – a five-year follow-up, European Clinical Respiratory Journal, 3:1, 32633

To link to this article: http://dx.doi.org/10.3402/ecrj.v3.32633

© 2016 Ane Stillits Måreng et al.
Primary pulmonary adenocarcinoma in children or adolescents is a rare disease, and as such, there are no randomised studies on lung cancer for this age group. Treatment choice is extrapolated from studies in adults (mean age of participants: 60 years). We present the 5-year follow-up of a 16-year-old boy who presented with metastatic primary pulmonary adenocarcinoma (T3N3M1a) and was treated aggressively, including radiation therapy for local and distant recurrence. He had complete remission, had completed his education, was employed full-time, and suffered only from mild side effects to treatment.

Keywords: non-small cell lung cancer; metastasis; survival; adolescent; diagnosis; survival

*Correspondence to: Uffe Bodtger, Department of Respiratory Medicine, Naestved Hospital, 61, Ringstedgade, DK-4700 Naestved, Denmark, Email: ubt@regionsjaelland.dk

Received: 15 June 2016; Revised: 5 October 2016; Accepted: 6 October 2016; Published: 7 November 2016

A 16-year-old Caucasian boy was admitted to our unit in January 2011 with a 2-month history of shortness of breath during exercise, haemoptysis, loss of appetite, and a weight loss of 3 kg. Labour, birth, and childhood had been unremarkable. There was no history of no tobacco smoke exposure, previous childhood cancer, environmental exposure to known carcinogens, or first- or second-generation relatives with cancer. He attended ninth grade, was active with sports, and lived in a rural town with his middle-class family. A chest x-ray showed a mass in right lower lobe (RLL). At admission, he presented with normal respiratory frequency, was slim but not underweight, and a fixed bronchial obstruction at auscultation in IC4 of the anterior left hemithorax.

A chest CT demonstrated two RLL lesions (T3), ipsi- and contralateral mediastinal lymphadenopathy (N3), and an intraluminal lesion obstructing left main bronchus (M1a) (Fig. 1). Bronchoscopy and endobronchial ultrasound confirmed Tumor-Node-Metastasis (TNM) stage: primary pulmonary adenocarcinoma with no signs of a foetal subtype (positive immunohistochemical staining to cytokeratine-7, TTF-1, and napsin with solitary cells additionally positive to cytokeratin-5, P63, and vimentin; all negative to placental alkaline phosphatase and synaptophysin). The patient underwent immediate bronchoscopic laser resection of tumour in the left main bronchus with immediate relief of dyspnea. Extensive histopathologically workup showed no mutations of EGFR, KRAS, or BRAF, no expression of ALK protein, no ALK-EML4 rearrangement, and no ROS1 translocation. Stage was confirmed by positron emission tomography (PET)-CT.

Downstaging was obtained with chemotherapy (nine courses of cisplatin, vinorelbine plus bevacizumab), thoracic radiation therapy (66 Gy on 33 fractions, 5 fractions/week), and additional three courses of platinum doublet.

Fig. 1. Contrast-enhanced chest CT at diagnosis. Arrows show tumour mass in left main bronchus (upper image) and in right lower lobe (lower image).
An FDG PET-CT scan showed complete regression of the left tumour. In April 2012, RLL was resected. Tumour islets identical with primary cancer were found in stations 7 and 12R. Postoperatively, he received adjuvant platinum-based chemotherapy.

Next-generation sequencing (Formalin-Fixed, Paraffin-Embedded tissue (FFPE)-purified genomic DNA; Ion AmpliSeq Cancer Hotspot Panel version 2) of the resected tumour revealed a non-targetable mutation in KIT gene (c.1676T > A, p.V559D). The other 49 genes were without mutations: ABL1, EZH2, JAK3, Pten, AKT1, FBXW7, IDH2, PTPN11, ALK, FGFR1, KDR, RB1, APC, FGFR2, RET, ATM, FGFR3, KRAS, SMAD4, BRAF, FLT3, MET, SMARCB1, CDH1, GNA11, MLH1, SMO, CDKN2A, GNAS, MPL, SRC, CSF1R, GNAQ, NOTCH1, STK11, CTNNB1, HNFI1, NPM1, TP53, EGFR, HRAS, NRAS, VHL, ERBB2, IDH1, PDGFRα, ERBB4, JAK2, and PIK3CA.

An FDG PET-CT scan was performed every 3 months. In October 2014, an FDG-positive mediastinal lesion was assessed by mediastinoscopy: no malignancy.

In April 2015, he underwent surgery for a solitary, symptomatic cerebral metastasis, followed by stereotactic radiation therapy (18 Gy × 1). In June 15, a biopsy-confirmed mediastinal and cervical lymph node recurrence was treated with nine series of docetaxel: partial remission after three courses and complete remission after nine courses. He continued clinical and PET-CT assessments every 3 months.

At 5-year follow-up (January 2016), he was without evidence of new recurrence. He had finished his commercial education and started an employment at a worldwide pharma industry. He had mild peripheral lower limb neuropathy as only side effect to treatment.

Discussion
The incidence of primary lung cancer in persons under 18 years is less than 0.05/100,000 persons, and primary pulmonary adenocarcinoma constitutes <10% of all cases (1–4). Benign or secondary malignant lesions in the lung are much more prevalent, though still rare. No specific oncogenic drivers, mutations, genes, tumour antigens, or other characteristics have been found in children or adolescents with primary pulmonary adenocarcinoma, though most patients have metastatic disease at presentation, and the 5-year survival is 25% (1, 2, 4). No randomised clinical trials on childhood primary lung cancer have been performed: almost an orphan disease, treatment strategies are extrapolated from studies conducted in older populations. In published reports on phase III-studies on first- or second-line therapy of unresectable lung adenocarcinoma, median age was 60 years, and less than 1% was below 30 years (5–19). Future studies on paediatric lung cancer will probably focus on genetic promoter mutations, as survival is improved when EGFR or KRAS mutations are present (20). Our patient had no targetable mutations.

An increasingly aggressive approach to advanced or metastatic non-small cell lung cancer (NSCLC) has emerged during the last years: intended curative chemoradiotherapy in locally advanced stages (21, 22), and intended curative surgery in M1b oligometastatic NSCLC with single brain metastasis and a small primary lesion (23). Our patient was offered extensive chemotherapy modified from guidelines for adult patients with stage IV primary pulmonary adenocarcinoma (24), and was successfully downstaged as assessed by both Response Evaluation Criteria In Solid Tumors (RECIST) criteria and invasive tissue sampling. Using an aggressive approach including surgical resection of single metastases, our patient had no signs of new relapse at the control visit 5 years after diagnosis and had only a minimum of persisting side effects.

Conflict of interest and funding
The authors have not received any funding or benefits from industry or elsewhere to conduct this study.

References
1. Yu DC, Grabowski MJ, Kozakewich HP, Perez-Atayde AR, Voss SD, Shamberger RC, et al. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg. 2010; 45: 1990–5.
2. Rojas Y, Shi YY, Zhang W, Beierle EA, Doski JJ, Goldfarb M, et al. Primary malignant pulmonary tumors in children: a review of the national cancer data base. J Pediatr Surg. 2015; 50: 1004–8.
3. Hartman GE, Shochat SJ. Primary pulmonary neoplasms of childhood: a review. Ann Thorac Surg. 1983; 36: 108–19.
4. Hancock B, Di Lorenzo M, Youssef S, Yazbeck S, Marcotte J, Collin P. Childhood primary pulmonary neoplasms. J Pediatr Surg. 1993; 28: 1133–6.
5. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432–40.
6. Ciuleanu T, Stelmakh L, Cienas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012; 13: 300–8.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123–32.
8. Garassino MC, Martelli O, Broggi M, Farina G, Veronesi S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14: 981–8.
9. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a
Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013; 119: 2754–64.
10. Shaw AT, Kim DW, Nakagawa K, Seto T, Cirió L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385–94.
11. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589–97.
12. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095–304.
13. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paez-Jones M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847–57.
14. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543–51.
15. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009; 27: 1227–34.
16. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92–8.
17. Soria JC, Mauguen A, Reck M, Sandler AB, Saito N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013; 24: 20–30.
18. Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009; 20: 1249–56.
19. Helbækko N, Sundström SH, Aasebo U, Brunsvig PF, von Plessen C, Hjelde HH, et al. Vinorelbine/carboplatin vs. gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007; 97: 283–9.